# Tamoxifen Prediction Study in Patients With ER+ Breast Cancer

> **NCT05525481** · PHASE4 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- ER+ Breast Cancer

## Interventions

- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT05525481
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-02-28
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525481, "Tamoxifen Prediction Study in Patients With ER+ Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05525481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*